Redeye: InDex Pharmaceuticals - Potential Blockbuster at a Discount

2022-08-29 07:54:00

Redeye revisits its assessment of InDex Pharmaceuticals ahead of the blinded interim analysis of CONCLUDE’s first induction study to choose dose for the remaining part of the pivotal study. We give our take on what is ahead for InDex in terms of the readout of induction study number one, financing of induction study number two, and partnering assumptions for EU5/Japan, among other things. We dilute our valuation and upgrade our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

MFN